Intellia Therapeutics (NTLA) officer reports 2,989-share tax sell-to-cover trade

Rhea-AI Filing Summary

Intellia Therapeutics VP and Chief Accounting Officer Michael P. Dube reported a small insider stock sale linked to tax withholding. On January 5, 2026, he sold 2,989 shares of Intellia common stock at $9.21 per share, leaving him with 52,277 shares held directly after the transaction.

According to the footnote, this was a mandatory “sell-to-cover” transaction carried out to satisfy his tax withholding obligations arising from the vesting of restricted stock units (RSUs) on January 1, 2026. The disclosure states that this sale does not represent a voluntary trading decision by the reporting officer but an automatic sale tied to equity award taxation.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dube Michael P

(Last) (First) (Middle)

C/O INTELLIA THERAPEUTICS, INC.

40 ERIE STREET; SUITE 130

(Street)

CAMBRIDGE MA 02139

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Intellia Therapeutics, Inc. [ NTLA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP, Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/05/2026		S(1)		2,989	D	$9.21	52,277	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2026, and does not represent a volitional trade by the Reporting Person.

	James Basta, attorney-in-fact	01/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Intellia Therapeutics (NTLA) report for Michael P. Dube?

Intellia Therapeutics reported that Michael P. Dube, its VP and Chief Accounting Officer, sold 2,989 shares of common stock on January 5, 2026 at $9.21 per share, leaving him with 52,277 shares held directly.

Was the Intellia (NTLA) insider stock sale by Michael P. Dube a discretionary trade?

No. The filing explains that the sale represents a mandatory “sell-to-cover” transaction to satisfy tax withholding obligations upon the vesting of RSUs on January 1, 2026 and does not represent a volitional trade by Michael P. Dube.

How many Intellia Therapeutics (NTLA) shares does Michael P. Dube hold after the reported sale?

After selling 2,989 shares, Michael P. Dube is reported to beneficially own 52,277 shares of Intellia common stock, held in direct ownership.

What role does Michael P. Dube hold at Intellia Therapeutics (NTLA)?

Michael P. Dube is identified as an officer of Intellia Therapeutics, serving as VP, Chief Accounting Officer, and he is not listed as a director or 10% owner.

What type of security was involved in the Intellia (NTLA) insider transaction on January 5, 2026?

The transaction involved Intellia Therapeutics common stock, with 2,989 shares sold at a price of $9.21 per share in a mandatory sell-to-cover sale.